Ifosfamide and vinorelbine combined chemotherapy in the treatment of advanced non-small cell lung cancer / 中国基层医药
Chinese Journal of Primary Medicine and Pharmacy
; (12)2006.
Article
em Zh
| WPRIM
| ID: wpr-679406
Biblioteca responsável:
WPRO
ABSTRACT
Objective To evaluate therapeutic effects and toxicity of advanced non-small cell lung cancer (NSCLC)treated by combining chemotherapy on ifosfamide(IFO)and vinorelbine(NVB).Methods 107 cases pa- tients with advanced NSCLC were enrolled.IFO was given in a dosage of 1.5g/m~2 on day 1 to 4.and NVB in a dosage of 25mg/m~2 on day 1 and 8.It was repeated every three or four weeks,up to two to four cycles.Results Two patients had complete response and 40 patients had partial response.The overall response rate was 47.7% ,the median survival time 10.3 months,1-year and 2-year survival rate was 42% and 12.3%,respectively.The main toxicity was bone marrow suppression.Conclusion The regimen is effective,sale and tolerable in advanced non- small cell lung cancer therapy.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Primary Medicine and Pharmacy
Ano de publicação:
2006
Tipo de documento:
Article